Hydroxyurea use in lebanese patients with β-thalassemia intermedia

Journal of Pediatric Hematology/Oncology

Volumn 28, Issue 2, 2006, Pages 107-

  Taher, Ali ^a,b   Sheikh Taha, Marwan ^c  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b Chronic Care Center Hazmieh   (Lebanon)

^c LEBANESE AMERICAN UNIVERSITY   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; HYDROXYUREA;

ADOLESCENT; ADULT; BETA THALASSEMIA; BLOOD TOXICITY; CLINICAL ARTICLE; DRUG EFFICACY; ETHNIC DIFFERENCE; HEMOGLOBIN DETERMINATION; HUMAN; LEBANON; LETTER; LIVER TOXICITY; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BETA-THALASSEMIA; CHILD; COMBINED MODALITY THERAPY; HUMANS; HYDROXYUREA; LEBANON; MIDDLE AGED; SPLENECTOMY; TREATMENT FAILURE; VARIATION (GENETICS);

EID: 33644633377     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mph.0000200671.39549.2b     Document Type: Letter

References (1)

1. Karimi M, Darzi H, Yavarian M. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J Pediatr Hematol Oncol. 2005;7:380-385.